Condition: Asthma
Interventions: Drug: RO4989991; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
Condition: Asthma
Interventions: Drug: Placebo; Drug: Tiotropium 5 µg q.d.; Drug: Tiotropium 2.5 µg b.i.d.
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Condition: Asthma
Interventions: Drug: FP 100mcg BID plus GSK2190915 100mg QD (AM); Drug: FP 100mcg BID plus GSK2190915 300mg QD (AM); Drug: FP 100mcg BID plus montelukast 10mg QD (PM); Drug: FP 100mcg BID plus placebo BID; Drug: FP/SAL 100/50mcg BID plus placebo BID
Sponsor: GlaxoSmithKline
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents
Condition: Asthma
Interventions: Drug: Fluticasone propionate inhalation powder; Drug: Fluticasone furoate inhalation powder; Drug: Placebo inhalation powder
Sponsor: GlaxoSmithKline
Recruiting – verified October 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Fall Epidemic Viral Pediatric Study
Condition: Asthma
Interventions: Drug: FLOVENT™ DISKUS™ 100 mcg BID; Drug: ADVAIR™ DISKUS™ 100/50 mcg BID
Sponsor: GlaxoSmithKline
Active, not recruiting – verified October 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
Condition: Asthma
Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder; Drug: Fluticasone Furoate Inhalation Powder; Drug: Placebo Inhaltion Powder
Sponsor: GlaxoSmithKline
Recruiting – verified October 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Association Between Fractional Exhaled Nitric Oxide and Asthma Control
Conditions: Bronchial Asthma; Nitric Oxide
Intervention:
Sponsor: Mahidol University
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II
Condition: Asthma
Interventions: Drug: 50 mcg salmeterol HFA MDI; Drug: placebo; Drug: 5 mcg tiotropium Respimat®; Drug: 2.5 mcg tiotropium Respimat®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Effect of Whole Body Periodic Acceleration on Airway Endothelial Function
Conditions: Healthy Control; Smokers; Asthma
Interventions: Device: Whole Body Periodic Acceleration (WBPA); Device: Sham WBPA
Sponsor: University of Miami
Recruiting – verified October 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler
Condition: Asthma
Interventions: Drug: Fluticasone furoate 50 mcg (4 inhalations); Drug: Fluticasone furoate 100 mcg (4 inhalations); Drug: Fluticasone furoate 200 mcg (4 inhalations); Drug: Vilanterol 25 mcg (4 inhalations)
Sponsor: GlaxoSmithKline
Not yet recruiting – verified October 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days